Galmed Pharmaceuticals
GLMD
19 hedge funds and large institutions have $1.21M invested in Galmed Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 8 closing their positions.
51% more capital invested
Capital invested by funds: $804K → $1.21M (+$410K)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
21% less funds holding
Funds holding: 24 → 19 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$37.2K |
| 2 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$5.24K |
| 3 |
Jane Street
New York
|
+$4.71K |
| 4 |
SG
StoneX Group
New York
|
+$3.67K |
| 5 |
AWM
Accurate Wealth Management
Wesley Chapel,
Florida
|
+$524 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$22K |
| 2 |
Renaissance Technologies
New York
|
-$16K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$11K |
| 4 |
WWM
Western Wealth Management
Golden,
Colorado
|
-$10.5K |
| 5 |
VF
Virtu Financial
New York
|
-$7K |
GLMD Hedge Fund Activity: Q4 2022 in Review
19 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2022, worth a combined $1.21M — up 51% from $804K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GLMD and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was Millennium Management, adding an estimated $37.2K. The largest seller was BVF Inc, cutting an estimated $22K.
- 19 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2022, down from 24 in Q3 2022.
- Funds reported $1.21M of Galmed Pharmaceuticals stock for Q4 2022, up 51% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q4 2022 and 8 closed out, a net change of -5 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $37.2K added.
- The largest Galmed Pharmaceuticals seller in Q4 2022 was BVF Inc, an estimated $22K sold.
Based on aggregated 13F filings for Q4 2022.